Page 2 - Pulse Bioscience News Today

Collaboration with CardioNXT provides navigation and mapping system integration with Pulse Biosciences’ nsPFA circumferential catheter to support first-in-human treatments ...

Pulse Biosciences (Nasdaq:PLSE) announced today that it entered into a collaboration with CardioNXT to support its AFib treatment.

Pulse Biosciences, Inc. , a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today announced...

Pulse Biosciences, Inc. , a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a...

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Pulse Biosciences...

Pulse Biosciences, Inc. , a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today provided...

Operator: Greetings, and welcome to Pulse Biosciences Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Key Insights Pulse Biosciences' significant insider ownership suggests inherent interests in company's expansion 76% of...

Pulse Biosciences, Inc. , a company leveraging its novel and proprietary nanosecond pulsed field ablation technology for the treatment of atrial fibrillation, today announced financial results for... | May 11, 2023

Paragon 28 (NYSE:FNA – Get Rating) and Pulse Biosciences (NASDAQ:PLSE – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends. Profitability This table compares Paragon 28 and Pulse Biosciences’ […]